-Advertisement-
-Advertisement-
FDA Alerts
FDA approves first IL-23 inhibitor for psoriatic arthritis
The U.S. Food and Drug Administration has approved guselkumab (TREMFYA; Janssen Pharmaceutical), the first selective interleukin (IL)-23 inhibitor for active psoriatic arthritis. In two Phase 3 clinical trials, guselkumab was found to significantly improvedssigns and symptoms in joints, skin, and soft tissue in adults with active psoriatic arthritis Guselkumab is...
Read More-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-
Contact
© 2024 Med Journal 360™ is a trademark of International Healthcare Media, LLC. All rights Reserved